CGEM Q2 2024 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q2 2024 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

-$77,000

Operating Income

-$50M

Net Income

-$42M

EPS (Diluted)

$-0.76

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$681M

Total Liabilities

$25M

Stockholders' Equity

$656M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$77,000	$0	—
Operating Income	-$50M	-$38M	-33.0%
Net Income	-$42M	-$32M	-30.5%